Evidence map›Paper›PMID 39721983›Full record

ArticleThe clinical respiratory journal2024

Liver Function Biomarkers and Lung Cancer Risk: A Prospective Cohort Study in the UK Biobank.

Xiangyu Sun, Zeqin Guo, Yanpei Zhang, Zhuangzhuang Liu, Jingrong Xiong, Mingliang Cai, Jiale Tan, Yan Lin, Zihang Yu, Kunheng Du and 2 more

Abstract read
In one paragraph

Article in The clinical respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiangyu SunDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zeqin GuoDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yanpei ZhangDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zhuangzhuang LiuDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jingrong XiongDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Mingliang CaiZhuhai People's Hospital, Jinan University, Zhuhai, China.
Jiale TanDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yan LinDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zihang YuDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Kunheng DuDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Enli LuDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiaolin XiaDepartment of Radiation Oncology, Yunfu People's Hospital, Yunfu, China.ORCID https://orcid.org/0009-0000-8846-0527

Funding

Medical Science and Technology Research Fund of Guangdong Province B2023094Research Foundation of YunFu People's Hospital A20221005
6 · The paper itself

Abstract

backgroundAs the primary organ of metabolism and detoxification, the liver may contribute to the pathogenesis of lung cancer. We aimed to illuminate the intricate link between liver function biomarkers and lung cancer risk, as well as delineate the role of smoking behavior within this association.

methodsWe investigated the associations of seven liver function biomarkers levels (alkaline phosphatase [ALP], alanine transaminase [ALT], total bilirubin [TBIL], albumin [ALB], gamma-glutamyltransferase [GGT], aspartate transaminase [AST], and total protein [TP]) with lung cancer risk across the UK Biobank (N = 337 499) through restricted cubic splines and Cox proportional hazards models. Moreover, Mendelian randomization (MR) was utilized to evaluate the causal effect of smoking behavior on these biomarkers. Then a lung cancer risk prediction model was developed among smokers by backward stepwise logistic regression.

resultsDuring a median follow-up of 13.3 years, 3003 lung cancer cases were identified. We found ALP levels positively associated with lung cancer risk, whereas ALT, TBIL, ALB, and AST were inversely correlated; TP exhibited a U-shaped association, whereas GGT displayed a mirrored J-shaped relationship. These associations were amplified among smokers. MR analysis indicated that smoking behavior could increase ALP (odds ratio [OR]: 1.05) and GGT (OR: 1.15) levels while decreasing TBIL (OR: 0.92), ALB (OR: 0.92), and TP (OR: 0.96) levels. The lung cancer risk model incorporating these biomarkers in smokers demonstrated robust discrimination.

conclusionOur finding provides perspectives and evidences towards the intricate crosstalk between the hepatic and pulmonary systems, as well as the processes through which tobacco catalyzes lung carcinogenesis.

Indexed as

Alkaline PhosphataseBiological Specimen BanksLung NeoplasmsSmokingAdultAgedAlanine TransaminaseAspartate AminotransferasesBilirubinBiomarkersFemalegamma-GlutamyltransferaseHumansLiverLiver Function TestsMaleAlanine TransaminaseAlkaline PhosphataseAspartate AminotransferasesBilirubinBiomarkersgamma-Glutamyltransferaseliver function biomarkerslung cancerMendelian randomizationrisk predictionsmoking

Identifiers

PMID39721983
PMCPMC11669495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.